Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Talen Energy Corp V.TLN


Primary Symbol: TLN

Talen Energy Corporation owns and operates power infrastructure in the United States. The Company produces and sells electricity, capacity, and ancillary services in wholesale power markets in the United States, primarily in PJM and WECC, with its generation fleet principally located in the Mid-Atlantic region of the United States and Montana. The majority of its generation is produced at its zero-carbon nuclear and lower-carbon gas-fired facilities. Its generation capacity is 10,665 megawatts (MW). Its segments include PJM and Other. The PJM segment is engaged in electricity generation, marketing activities, commodity risk and fuel management within the PJM RTO or ISO markets and comprises Susquehanna and Talen’s natural gas and coal generation facilities. Its Other segment includes the operating and marketing activities of Talen Montana’s proportionate share of the Colstrip Units in the WECC market, the operating activities of Nautilus, and other development activities.


NDAQ:TLN - Post by User

Bullboard Posts
Post by Everswanon May 15, 2009 3:24pm
164 Views
Post# 15996930

ASCO Conference

ASCO Conference

ASCO conference at the end of May 2009.

 

I guess the new drug landscape is pretty much set by now.

 

Tarceva is weak, has new undesirable side effects.

Iressa has revived

Bristol-Squidd/Exelixis is gearing up as a threat to all. However, significant side-effects are now noteworthy…

Other known drugs are failing trials.

 

Biomarkers are now set up to filter cancer patients, shrinking market for existing cancer drugs.

 

KRAS is the buzz word.

 

I guess the logical conclusion would be that TLN-4601 is a strategic investment for all to consider. The competitive landscape pushes for a takeover of TLN. It’s was obvious now it’s even clearer.

 

The odds for a lucrative Takeover just got better. Nice Friday.

 

Market is going stir attention toward the oncology sub-segment as a new defensive-growth area.  

Bullboard Posts

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse